Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow TRVI by emailGet an email when TRVI pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about TRVI, unsubscribe in one click. Privacy
📣 What TRVI Says Is Next
second half of 2027 · “The Company will report the outcome of the SSRE once available and expects to report topline results from the trial in the second half of 2027.”
Company press release, Aug 6, 2026 · SEC filing
fourth quarter of 2026 · “The protocol includes a sample size re-estimation (SSRE) analysis once 50% of the participants complete treatment which is expected to occur in the fourth quarter of 2026.”
Company press release, Aug 6, 2026 · SEC filing
first half of 2028 · “Topline data from the 52-week fixed dosing OCEAN-1 trial is expected in the first half of 2028.”
Company press release, Aug 6, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full TRVI picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TRVI and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.